U.S. Court of Appeals for the District of Columbia Circuit
Braeburn Inc. v. U.S. Food & Drug Admin.
This writing
- Type
- Opinion of the Court
- Filed
- July 22, 2019
- Case
- Braeburn Inc. v. U.S. Food & Drug Admin.
- Case status
- Decided
Source No authoring judge could be established for this writing, either from provider metadata or from the signature line of the court's published opinion. Benchlight shows the gap rather than guessing at an author.
Opening text
The first passage of the document, as extracted by the source provider.
BERYL A. HOWELL, Chief Judge Both the plaintiff, Braeburn Inc., and the intervenor-defendant, Indivior Inc., are pharmaceutical companies that manufacture drug products using buprenorphine, a safer alternative to methadone, to treat moderate-to-severe opioid use disorder ("OUD"). All parties recognize the serious national public health problem posed by OUD and the need for effective treatment options for patients with this addictio…
Source Extract supplied by CourtListener. Benchlight does not host the document — read the authoritative text in the court's own PDF.